Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Post by narmacon Jun 09, 2022 6:40am
154 Views
Post# 34742699

Blood-Brain Barrier Market Size to Reach USD 7.40 Billion.

Blood-Brain Barrier Market Size to Reach USD 7.40 Billion. ,,,,Get um while you can!!!,,,,,,what an opportunity for new investors,,,,,ones not adverse to risk......bring it on DrDR!!!!

Blood-Brain Barrier Market Size to Reach USD 7.40 Billion in 2028 | Rising Adoption of Advanced Techniques for Treating Acute Neurological Disorders are Factors Fueling Industry Growth, says Emergen Research.


Key players operating in the Blood-Brain Barrier market are Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG.

<< Previous
Bullboard Posts
Next >>